---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-24-000169"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:31:25.946656+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised

## Summary
- Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
- GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.
- Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.
- FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.
- Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024.

## SEC filing metadata
- accession: 0000879169-24-000169
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/0000879169-24-000169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/incy-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-24-000169
- JSON: https://secwatch.observer/filing/0000879169-24-000169.json
- Plain text: https://secwatch.observer/filing/0000879169-24-000169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.